{'fraction_non_alphanumeric': 0.017857142857142856, 'fraction_numerical': 0.007936507936507936, 'mean_word_length': 6.006944444444445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation

cirrhotic patients. Unfortunately, issues of generalisability in the aforementioned trial prevent definitive conclusions about the impact of transfusion policy on the outcomes of patients with nonvariceal bleeding; importantly, additional information will soon be available from a cluster randomized trial in the United Kingdom. In the interim, based on all currently available evidence, clinicians should continue to follow consensus recommendations for patients with nonvariceal bleeding. We would also like to correct Dr Lin regarding his comments about current recommendations. The 2010 International Consensus Group in fact suggested a restrictive transfusion practice, with blood transfusions administered to patients with a haemoglobin level of 7 g/dL or less, pending further data. Furthermore, threshold haemoglobin levels of 6–10 g/dL may warrant transfusion in patients with underlying cardiac disease.